Entry6.28→Now6.42
Cheap cash-generative needle maker; GLP-1 fear overdone, deleveraging Open original source
EMBC Embecta Corp. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
17:41
Oct 17
Oct 17
r/ValueInvesting
Cheap cash-generative needle maker; GLP-1 fear overdone, deleveraging
The author argues Embecta, the global leader in insulin pen needles and syringes, trades at roughly 4x earnings after a May guidance cut and 58% single-day drop, so the bad news is largely priced in while a recovery is not. The bull mechanism is a sticky, consumable diabetic installed base that GLP-1 drugs do not eliminate, plus management deleveraging quarter after quarter and the Owen Mumford acquisition widening the business beyond pen needles; every dollar of debt paid down transfers value to shareholders. Catalysts are fiscal Q4/full-year results in November as the first read on US pen needle stabilization, followed by debt paydown and Owen Mumford contribution, with a $11 base case and $21 three-year target. Stated risks include continued US share loss, damaged management credibility after the May cut, active securities litigation and microcap volatility.
EMBC
Embecta Corp.
Long
1ST
Position: Holding
—
About EMBC Investor Commentary
Across the available history and selected sources, Buzzberg tracks EMBC (Embecta Corp.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/Confident_Key_5228.